Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3

Status

Recruiting 2Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2NETWORK 1

Study Type

Interventional 6Observational 3Expanded_access 1

Sponsor

Cancer Type

CNS 5Lymphoid 1

Conditions

Astrocytoma 3Glioma 2Oligodendroglioma 1Lymphoma, Follicular 1Healthy Adult Participants 1Brain Neoplasms 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × vorasidenib × Clear all
NCT06809322 2026-05-22

VIGOR

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Recruiting
468 enrolled
CNS

Astrocytoma

NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Servier

Phase 1 Completed
28 enrolled

Healthy Adult Participants

NCT07215910 2025-10-14

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
408 enrolled
CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT05609994 2025-07-18

ViCToRy

Duke University

Phase 1 Recruiting
48 enrolled
CNS

Brain Neoplasms, Glioma

NCT04164901 2025-04-03

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Servier

Phase 3 Active not recruiting
331 enrolled 25 charts 1 FDA
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡